Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Aflibercept for Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in Germany: Twelve-Month Outcomes of PERSEUS.

Framme C, Eter N, Hamacher T, Hasanbasic Z, Jochmann C, Johnson KT, Kahl M, Sachs H, Schilling H, Thelen U, Wiedemann P, Wachtlin J; Prospective Noninterventional Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients with Neovascular Age-Related Macular Degeneration Study Group.

Ophthalmol Retina. 2018 Jun;2(6):539-549. doi: 10.1016/j.oret.2017.09.017. Epub 2017 Nov 20.

PMID:
31047606
2.

Challenges and opportunities of power systems from smart homes to super-grids.

Kuhn P, Huber M, Dorfner J, Hamacher T.

Ambio. 2016 Jan;45 Suppl 1:S50-62. doi: 10.1007/s13280-015-0733-x.

3.

Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension.

Gandolfi SA, Lim J, Sanseau AC, Parra Restrepo JC, Hamacher T.

Adv Ther. 2014 Dec;31(12):1213-27. doi: 10.1007/s12325-014-0168-y. Epub 2014 Nov 28.

4.

Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension.

Lanzl I, Hamacher T, Rosbach K, Ramez MO, Rothe R, Růžičková E, Karhanová M, Kimmich F.

Clin Ophthalmol. 2013;7:901-10. doi: 10.2147/OPTH.S41640. Epub 2013 May 16.

5.

Nonregenerative natural resources in a sustainable system of energy supply.

Bradshaw AM, Hamacher T.

ChemSusChem. 2012 Mar 12;5(3):550-62. doi: 10.1002/cssc.201100563. Epub 2012 Feb 20.

PMID:
22351622
6.

Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.

Uusitalo H, Chen E, Pfeiffer N, Brignole-Baudouin F, Kaarniranta K, Leino M, Puska P, Palmgren E, Hamacher T, Hofmann G, Petzold G, Richter U, Riedel T, Winter M, Ropo A.

Acta Ophthalmol. 2010 May;88(3):329-36. doi: 10.1111/j.1755-3768.2010.01907.x.

7.

Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis.

Hamacher T, Airaksinen J, Saarela V, Liinamaa MJ, Richter U, Ropo A.

Acta Ophthalmol Suppl (Oxf ). 2008;242:14-9. doi: 10.1111/j.1755-3768.2008.01381.x.

PMID:
18752510
8.

Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies.

Hamacher T, Schinzel M, Schölzel-Klatt A, Neff HM, Maier H, Schlaffer G, Beausencourt E, Jütte M, Scholz R, Lorger C, Stewart WC.

Br J Ophthalmol. 2004 Oct;88(10):1295-8.

9.

K+ channel interactions detected by a genetic system optimized for systematic studies of membrane protein interactions.

Obrdlik P, El-Bakkoury M, Hamacher T, Cappellaro C, Vilarino C, Fleischer C, Ellerbrok H, Kamuzinzi R, Ledent V, Blaudez D, Sanders D, Revuelta JL, Boles E, André B, Frommer WB.

Proc Natl Acad Sci U S A. 2004 Aug 17;101(33):12242-7. Epub 2004 Aug 6.

10.

Homo- and hetero-oligomerization of ammonium transporter-1 NH4 uniporters.

Ludewig U, Wilken S, Wu B, Jost W, Obrdlik P, El Bakkoury M, Marini AM, André B, Hamacher T, Boles E, von Wirén N, Frommer WB.

J Biol Chem. 2003 Nov 14;278(46):45603-10. Epub 2003 Sep 2.

11.

Characterization of the xylose-transporting properties of yeast hexose transporters and their influence on xylose utilization.

Hamacher T, Becker J, Gárdonyi M, Hahn-Hägerdal B, Boles E.

Microbiology. 2002 Sep;148(Pt 9):2783-8.

PMID:
12213924

Supplemental Content

Loading ...
Support Center